Search

Your search keyword '"Shekari, Mahnaz"' showing total 73 results

Search Constraints

Start Over You searched for: Author "Shekari, Mahnaz" Remove constraint Author: "Shekari, Mahnaz" Database Supplemental Index Remove constraint Database: Supplemental Index
73 results on '"Shekari, Mahnaz"'

Search Results

1. Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology.

2. Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study.

3. Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression.

4. The associations between glial biomarkers and cognitive changes in individuals at risk of Alzheimer's disease.

5. Reproductive span as a modifier of the association between AD biomarkers and cognitive decline in cognitively unimpaired women.

6. Amyloid‐PET Centiloid quantification predicts cognitive functioning in a pre‐dementia population: findings from AMYPAD‐PNHS.

7. Exploring biomarker profiles of the cognitively unimpaired individuals in early tau PET Braak stage.

8. Evaluating the sensitivity of Centiloid quantification to pipeline design and image harmonization.

9. A Centiloid cut‐off to help predict true amyloid accumulation.

10. Comparing parametric methods for longitudinal measurement of β‐amyloid pathology with PET in elderly individuals.

11. Cognitively Unimpaired Multiparous Women Have Higher CSF p‐tau181 Levels Which Have More Deleterious Effects on Neurodegeneration and Executive Function.

12. Plasma biomarkers rates of change across the preclinical stage of Alzheimer's disease: a longitudinal study.

13. A Centiloid cut‐off to help predict true amyloid accumulation.

14. Evaluating the sensitivity of Centiloid quantification to pipeline design and image harmonization.

15. Amyloid‐PET Centiloid quantification predicts cognitive functioning in a pre‐dementia population: findings from AMYPAD‐PNHS.

16. Exploring biomarker profiles of the cognitively unimpaired individuals in early tau PET Braak stage.

17. Differential effects of sleep on brain structure and metabolism at the preclinical stages of AD.

18. Increased cerebral blood flow is associated with higher baseline amyloid burden in a cognitively unimpaired population.

19. Quantifying AD‐related brain amyloid with linearised progression models: Model‐based vs. data‐based.

20. Quantification of [18F]florbetaben amyloid‐PET imaging in a mixed memory clinic population: The ABIDE project.

21. Amyloid predicts longitudinal atrophy in non‐demented individuals: Results from the AMYPAD Prognostic & Natural History study.

22. Optimizing plasma biomarkers combinations for the detection of amyloid pathology in cognitively unimpaired individuals.

23. CSF sTREM2 and YKL‐40 modify the balance between soluble and fibrillary β‐amyloid in non‐demented individuals.

24. Brain‐age mediates the association between modifiable risk factors and cognitive decline early in the AD continuum.

25. CSF Aβ42/40 is associated with neurodegeneration independently of CSF p‐tau in the earliest AD continuum.

26. Self‐reported COVID‐19 and biomarkers of Alzheimer's disease: interim analyses from an Alzheimer's disease risk‐enriched cohort.

27. Different astrocyte phenotypes mediate the pathological cascade early in the Alzheimer's disease continuum.

28. Differential associations between regional amyloid PET and Alzheimer's disease polygenic risk scores.

29. Comparing parametric methods for longitudinal measurement of β‐amyloid pathology with PET in elderly individuals.

30. Brain‐age mediates the association between modifiable risk factors and cognitive decline early in the AD continuum.

31. CSF Aβ42/40 is associated with neurodegeneration independently of CSF p‐tau in the earliest AD continuum.

32. Differential associations between regional amyloid PET and Alzheimer's disease polygenic risk scores.

33. Self‐reported sleep quality interacts with Alzheimer's disease biomarkers on brain structure and metabolism in cognitively unimpaired adults.

34. Evaluating the sensitivity of Centiloid quantification to pipeline design and image resolution.

35. Voxel‐wise Staging of Tau Pathology using [18F]RO‐948 PET in the Early AD Continuum.

36. [18F]RO‐948 Tau PET Retention and Correlation with Fluid Tau Biomarkers in the Early AD Continuum.

37. Evaluating the sensitivity of Centiloid quantification to pipeline design and image resoloution.

38. Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi‐Cohort Validation Against Biomarkers of Alzheimer's Disease and Neurodegeneration.

39. Quantifying AD‐related brain amyloid with linearised progression models: model‐based vs. data‐based.

40. Overestimation of performance after a memory task in cognitively unimpaired individuals is related to lower cortical thickness in Alzheimer's disease vulnerable regions and to executive decline, particularly in men.

41. Associations between brain iron deposition and structural Alzheimer's disease signature in cognitively unimpaired adults.

42. Associations between brain iron deposition and structural Alzheimer's disease signature in cognitively unimpaired adults.

43. Imaging neurodegeneration markers are associated with multiple pathophysiological mechanisms in the early stages of the Alzheimer’s continuum.

44. CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study.

45. Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts

46. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

47. Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum.

48. The effects of a 24‐weeks resistance exercise intervention on global brain amyloid beta levels: Preliminary results of AGUEDA randomized controlled trial.

49. Associations between gait velocity parameters and brain amyloid‐β levels in cognitive normal older adults: a cross‐sectional analysis from the AGUEDA trial.

50. Association between blood pressure and Alzheimer's disease biomarkers in cognitively unimpaired adults.

Catalog

Books, media, physical & digital resources